The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...

As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections (uUTIs ...

Catalent is laying off 350 employees in its gene therapy manufacturing division in Baltimore “due to an unexpected shift in ...

A trio of Indian drugmakers—Alembic Pharmaceuticals, Sun Pharmaceutical and Glenmark Pharmaceuticals—issued separate ...

Leo reported that sales of eczema treatment Adbry are scaling up in the U.S. The company also made a positive adjustment to its 2025 sales guidance.

As its lead candidate advances into a late-stage trial, Inhibikase has picked up a commercial leader with plenty of experience in the PAH space.

With a win in a D.C. appeals court, Vanda Pharmaceuticals has earned a point over the FDA in the yearslong face-off between ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...